Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Science 16 January 1998:
Vol. 279. no. 5349, pp. 323 - 324
DOI: 10.1126/science.279.5349.323

Research News

CANCER RESEARCH:
Peptide-Guided Cancer Drugs Show Promise in Mice

Marcia Barinaga

Chemotherapeutic drugs spread throughout the body, reaching not only the tumor but also healthy organs, where they kill off normal dividing cells. Tumor cells are also quick to mutate and become resistant to the drugs. Now, on page 377, a research team reveals a strategy that may get around both problems, by targeting cancer drugs to the new blood vessels that nourish the tumor. They found small peptides that zero in on the cells lining these newly formed blood vessels, then linked the peptides to the chemotherapeutic drug doxorubicin. By addressing the toxic drug specifically to the tumor, the strategy spares other tissues. And because the tumor vessel cells are not cancerous themselves, they are much less likely to develop resistance to the drugs. Indeed, when the researchers gave the peptide-drug combination to mice with large tumors, it killed off the blood vessels, stopped tumor growth, and allowed the mice to survive the cancer. What's more, the technique used to identify peptides that home in on tumor vessels can identify peptides that bind specifically to the blood vessels of other organs, meaning that peptides could be developed to carry drugs to many different tissues to treat conditions other than cancer.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Vascular Growth Factors and Lymphangiogenesis.
L. Jussila and K. Alitalo (2002)
Physiol Rev 82, 673-700
   Abstract »    Full Text »    PDF »



To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)